Systemic immune-inflammation index as a prognostic biomarker to predict overall survival after primary stereotactic radiosurgery for brain metastases - Summary - MDSpire
Advertisement
Systemic immune-inflammation index as a prognostic biomarker to predict overall survival after primary stereotactic radiosurgery for brain metastases
To evaluate the prognostic value of systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) for predicting overall survival (OS) and local tumor control (LC) duration after primary stereotactic radiosurgery (SRS) for brain metastases, emphasizing the importance of both metrics.
Key Findings:
Higher SII and SIRI values were associated with worse overall survival, indicating a need for careful patient monitoring.
SII and SIRI may serve as objective biomarkers to enhance prognostic accuracy beyond DS-GPA, potentially improving treatment strategies.
The study highlights the potential of using blood-based biomarkers in clinical decision-making for brain metastases, suggesting a shift towards more personalized treatment approaches.
Interpretation:
The findings suggest that SII and SIRI are valuable prognostic indicators for patients undergoing SRS for brain metastases, potentially aiding in more accurate survival predictions.
Limitations:
The study's retrospective design may introduce bias, affecting the reliability of the findings.
Limited number of events for local control analysis restricts definitive conclusions.
Generalizability may be affected due to the specific patient population and treatment protocols.
Conclusion:
SII and SIRI are promising biomarkers for predicting overall survival in patients treated with SRS for brain metastases, warranting further investigation in larger cohorts to validate their clinical utility.
A Keck Medicine of USC neurointerventionalist discusses how a minimally invasive, endovascularly implantable cerebrospinal fluid shunt is the next-generation treatment for normal pressure hydrocephalus — and possibly more.
